{"algorithm_version": "v0.6.0", "applied_rules": {"base_min_final_score": 68.0, "min_bullish_analyses": 2, "min_confidence": 0.62, "min_final_score": 70.0, "min_liquidity_avg_volume": 750000, "regime": "mixed", "regime_score_delta": 2.0}, "benchmark": "SPY", "catalysts": ["September 30, 2026: A federal court found that Liquidia’s Yutrepia infringes two valid United Therapeutics patent claims covering inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease. The ruling could strengthen Tyvaso’s competitive position.", "September 30, 2026: The court directed the parties to submit a proposed final judgment within one week. United Therapeutics is seeking remedies that could restrict Yutrepia’s availability, creating a possible near-term follow-up catalyst.", "A court win against Liquidia protects United Therapeutics' key drug Tyvaso from competition.", "The court will soon decide on remedies, which could further limit Liquidia's product.", "A federal court ruled that Liquidia's competing drug Yutrepia infringes United Therapeutics' patents, protecting its key revenue-generating drug Tyvaso from a major rival."], "company_name": "United Therapeutics", "conviction": "high", "data_quality": 0.8825000000000001, "date": "2026-10-01", "favorable_models_count": 3, "final_confidence": 0.7560299278217089, "final_score": 84.894, "generated_at": "2026-10-01T07:30:00.005997-04:00", "horizon": "intraday", "models_answered": 3, "models_asked": 3, "quantitative_score": 76.61, "reason": null, "regulatory_warning": "This is automated, general-audience analysis published for informational purposes only. It is not a personal recommendation, not a promise of performance, and not an invitation to buy or sell any financial instrument. Every investment can lose value, and past results do not predict future ones.", "risks": ["The patent ruling was not an unconditional victory: the court invalidated other asserted claims, and Liquidia intends to appeal.", "The final remedy has not yet been determined; the court could decline to impose the strongest restrictions sought by United Therapeutics.", "The stock has already risen sharply, so some investors may take profits.", "Liquidia plans to appeal, which could create new legal uncertainty.", "The stock has already surged over 12% in five days, meaning much of the good news may already be priced in and profit-taking could push it lower."], "shortfalls": [], "status": "signal", "summary": "The clearest next-session catalyst is the September 30 patent win against Liquidia, which may protect Tyvaso from Yutrepia competition and could lead to additional headlines when the court addresses remedies within roughly a week. The FDA filing acceptance and accelerated share repurchase add longer-term support, but the stock’s sharp recent rise makes near-term profit-taking a meaningful risk.", "ticker": "UTHR", "timezone": "Europe/Zurich", "watchlist": []}